SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Mengdie Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, Center for Global Health, School of Public Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention, and Tr…. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Neoplastic Stem Cells, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Science, Technology and Education.
Abstract (Originalsprache)
Background
The high fatality rate of glioblastoma (GBM) is attributed to glioblastoma stem cells (GSCs), which exhibit heterogeneity and therapeutic resistance. Metabolic plasticity of mitochondria is the hallmark of GSCs. Targeting mitochondrial biogenesis of GSCs is crucial for improving clinical prognosis in GBM patients.
Methods
SMYD2-induced PGC1α methylation and followed nuclear export are confirmed by co-immunoprecipitation, cellular fractionation, and immunofluorescence. The effects of SMYD2/PGC1α/CRM1 axis on GSCs mitochondrial biogenesis are validated by oxygen consumption rate, ECAR, and intracranial glioma model.
Results
PGC1α methylation causes the disabled mitochondrial function to maintain the stemness, thereby enhancing the radio-resistance of GSCs. SMYD2 drives PGC1α K224 methylation (K224me), which is essential for promoting the stem-like characteristics of GSCs. PGC1α K224me is preferred binding with CRM1, accelerating PGC1α nuclear export and subsequent dysfunction. Targeting PGC1α methylation exhibits significant radiotherapeutic efficacy and prolongs patient survival.
Conclusions
These findings unveil a novel regulatory pathway involving mitochondria that govern stemness in GSCs, thereby emphasizing promising therapeutic strategies targeting PGC1α and mitochondria for the treatment of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Food Hygiene, Center for Global Health, School of Public Health, Jiangsu Key Lab of Cancer Biomarkers, Prevention, and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personaliz…
- National Health Commission Key Laboratory of Antibody Techniques, Department of Cell Biology, Jiangsu Provincial Key Laboratory of Human Functional Genomics, School of Basic Medical Sciences, Nanjing Medical University,…
- Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Xin Ge, Zhumei Shi
Förderung
- National Natural Science Foundation of China
- Science, Technology and Education
Zitieren
APA
Li, M., Zhang, Z., He, L., Wang, X., Yin, J., Wang, X., You, Y., Qian, X., Ge, X., & Shi, Z. (2024). SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae090
Vancouver
Li M, Zhang Z, He L, Wang X, Yin J, Wang X, et al. SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae090
BibTeX
@article{Li2024,
author = {Li, Mengdie and Zhang, Zhixiang and He, Liuguijie and Wang, Xiefeng and Yin, Jianxing and Wang, Xiuxing and You, Yongping and Qian, Xu and Ge, Xin and Shi, Zhumei},
title = {SMYD2 induced PGC1α methylation promotes stemness maintenance of glioblastoma stem cells},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae090}
}
EUVIMED